PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM

• Scott Kolodny,
• Michael Vredenburg,
• Jessica Zhang,
• Brian Jamieson

Affiliations

Scott Kolodny

1 Sobi Pharmaceuticals, Medical Affairs, Durham, United States

Michael Vredenburg

2 Sobi Pharmaceuticals, Medical Affairs, Durham, United States

Jessica Zhang

3 Sobi Pharmaceuticals, Clinical Development, Durham, United States

Brian Jamieson

3 Sobi Pharmaceuticals, Clinical Development, Durham, United States